Background <p>Prostate cancer (PCa) is a prevalent malignancy with limited treatment options for advanced stages. Oncolytic virotherapy represents a promising immunotherapeutic approach, but its efficacy and underlying mechanisms in PCa, particularly concerning immune checkpoint regulation, remain unclear.</p> Methods <p>The antitumor effects of the oncolytic virus oncolytic herpes simplex virus type 2 (OH2) were evaluated in PCa cell lines and mouse…
Oncolytic virus OH2 induces PD-L1 upregulation via NF-{kappa}B signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system
Journal for ImmunoTherapy of Cancer | | Xu, J.-Z., An, Y., Sun, J.-X., Xiong, Y.-F., Liu, C.-Q., Zhang, S.-H., Xia, Z.-Y., Hu, J., Zhang, Z.-Y., Guo, C.-X., Liu, B.-L., Guan, W., Wang, S.-G., Xia, Q.-D.
Topics: prostate-cancer, immunotherapy, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer